- BlackRock’s XDNA ETF linked to blockchain project on XRPL.
- DNA Protocol’s discreet presale raises questions over institutional access.
- Speculation grows as BlackRock and Ripple remain publicly silent.
According to market commentator Pumpius, BlackRock may have an indirect involvement in a blockchain initiative operating on the XRP Ledger. He associates one of the assets of the asset manager, iShares Genomics and Healthcare ETF, with the ticker XDNA, with a decentralized blockchain initiative that also operates under the same ticker.
DNA Protocol, the blockchain project in question, is focused on storing and managing genomic and bioinformatics data through its Genomechain platform. The same ticker symbol and thematically close orientation were offered as evidence of a potential affiliation.
“It’s a perfect mirror of BlackRock’s ETF. A corporate ETF and its decentralized, on-chain twin,” Pumpius said.
XRPL as an Institutional Blockchain
Pumpius noted that the XRP Ledger offers features suited to institutional adoption, including low transaction fees, rapid settlement, and established relationships with the banking sector. These features make it a rational selection for a high-value data tokenization initiative.
🧵 The Unseen Hand of BlackRock in XRPL – A Deep Dive
What I’m about to share is not public knowledge. I’ve spent weeks connecting dots that Wall Street hopes you’ll ignore.
Pay attention. 👇🧵 pic.twitter.com/QYnkkiEC1E
— Pumpius (@pumpius) August 10, 2025
Also Read: Major Cryptocurrencies Decline in 24 Hours as Smaller Altcoins Post Strong Gains
Two DNA Protocol websites, a presale portal, and a Genomechain site were mentioned as illustrations of the project’s discrete online presence. They are described as accessible but not actively promoted, which he interprets as a strategic decision to operate without public attention while building infrastructure.
Funding and Asset Tokenization Plans
The presale portal is presented as evidence of a private funding phase aimed at institutional clients. Pumpius claims that the XDNA project could serve as a pilot for broader tokenization efforts. Should genomic data be successful, the same approaches could be used to tokenize bonds, equities, and properties.
Neither BlackRock nor Ripple has issued statements to comment on such allegations. According to Pumpius, this lack of official reaction is characteristic of the situation’s interpretation.
It is important to note however that Pumpius’ allegations remain unverified, and there is no official confirmation of any connection between BlackRock and DNA Protocol. However, the claims have nonetheless generated substantial interest within the XRP community, contributing to ongoing discussions about institutional engagement in blockchain projects.
Also Read: VeChain (VET) Price Prediction 2025–2030: Will VET Hit $0.02722 Soon?
